Decision Support Tool to Individualize Cyclosporine Dose in Stable, Long-term Heart Transplant Recipients Receiving Metabolic Inhibitors: Overcoming Limitations of Cyclosporine C2 Monitoring

Journal of Heart and Lung Transplantation

Volumn 25, Issue 10, 2006, Pages 1223-1229

  Ray, John E ^a   Keogh, Anne M ^a   McLachlan, Andrew J ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DILTIAZEM; KETOCONAZOLE;

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; COMPUTER PROGRAM; DRUG METABOLISM; FEMALE; GRAFT RECIPIENT; HEART GRAFT; HUMAN; LONG TERM CARE; MALE; MEDICAL DECISION MAKING; PREDICTION; PRIORITY JOURNAL;

AREA UNDER CURVE; BAYES THEOREM; CARDIOVASCULAR AGENTS; CYCLOSPORINE; DECISION SUPPORT TECHNIQUES; DILTIAZEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEEDBACK, BIOCHEMICAL; FEEDBACK, PHYSIOLOGICAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KETOCONAZOLE; PREDICTIVE VALUE OF TESTS; TIME FACTORS;

EID: 33749533786     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2006.07.002     Document Type: Article

References (40)

1. Cantarovich M., Barkun J., Giannetti N., Cecere R., Besner J., and Tchervenkov J. History of C2 monitoring in heart and liver transplant patients treated with cyclosporine microemulsion. Transplant Proc 36 suppl (2004) 442S-447S
2. Lindholm A., and Kahan B. Influence of cyclosporin pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 54 (1993) 205-218
3. Citterio F. Evolution of the therapeutic drug monitoring of cyclosporin. Transplant Proc 36 suppl (2004) 420S-425S
4. Balram C., Sivathasan C., Cheung Y., Tan S., and Tan Y. A limited sampling strategy for the estimation of 12-hour Neoral systemic drug exposure in heart transplant recipients. J Heart Lung Transplant 21 (2002) 1016-1021
5. Mathias H., Ozalp F., Will M., et al. A randomized, controlled trial of C0 vs C2 guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients. J Heart Lung Transplant 24 (2005) 2137-2143
6. Delgado D., Rao V., Hamel J., Miriuka S., Cusimano R., and Ross H. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes. J Heart Lung Transplant 24 (2005) 1343-1346
7. Diciolla F., Scolletta S., Berti L., et al. C2 and C0 values for monitoring cyclosporine therapy in stable heart transplant recipients. Transplant Proc 37 (2005) 1355-1359
8. Einecke G., Schutz M., Mai I., et al. Limitations of C2 monitoring in renal transplant recipients. Nephrol Dial Transplant 20 (2005) 1463-1470
9. Ray J., Keogh A., McLachlan A., and Akhlaghi F. Cyclosporin C2 and C0 concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors. J Heart Lung Transplant 22 (2003) 715-722
10. Trull A., Steel L., Sharples L., et al. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in De Novo lung transplant recipients. Ther Drug Monit 21 (1999) 17-26
11. Zakliczynski M., Krynicka A., Szewczyk M., Wojarski J., and Zembala M. Limited utility of cyclosporine C2 monitoring in heart transplant recipients receiving ketoconazole. Transplant Proc 35 (2003) 2333-2334
12. Wacke R., Rohde B., Engel G., et al. Comparison of several approaches of therapeutic drug monitoring of cyclosporin A based on individual pharmacokinetics. Eur J Clin Pharmacol 56 (2000) 43-48
13. Villamil F., and Pollard S. C2 monitoring of cyclosporin in de novo liver transplant recipients: the clinician's perspective. Liver Transplant 10 (2004) 577-583
14. Birsan T., Loinig C., Bodingbauer M., et al. Comparison between C0 and C2 monitoring in de novo renal transplant recipients: retrospective analysis of a single-centre experience. Transplantation 78 (2004) 1787-1791
15. Martin K., Begaud B., Latry P., Miremont-Salame G., Fourrier A., and Moore N. Differences between clinical trials and postmarketing use. Br J Clin Pharmacol 57 (2003) 86-92
16. Ruggeri A., and Martinelli M. A program for the optimization of cyclosporine therapy using population kinetics modeling. Comput Meth Progr Biomed 61 (2000) 61-69
17. Bourgoin H., Paintaud G., Buchler M., et al. Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients. Br J Clin Pharmacol 59 (2005) 18-27
18. Langers P., Cremers S., Den Hartigh J., et al. Easy-to-use, accurate and flexible individualized Bayesian limited sampling method without fixed time points for ciclosporin monitoring after liver transplantation. Aliment Pharmacol Ther 21 (2005) 549-557
19. Wu G. An explanation for failure to predict cyclosporin area under the curve using limited sampling strategy: a beginner's second note. Pharmacol Res 35 (1997) 547-552
20. Parke J., and Charles B. Factors affecting oral cyclosporin disposition after heart transplantation: bootstrap validation of a population pharmacokinetic model. Eur J Clin Pharmacol 56 (2000) 481-487
21. Rosenbaum S., Baheti G., Trull A., and Akhlaghi F. Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. Ther Drug Monit 27 (2005) 116-122
22. Rousseau A., Monchaud C., Debord J., et al. Bayesian forecasting of oral cyclosporin pharmacokinetics in stable lung transplant recipients with and without cystic fibrosis. Ther Drug Monit 25 (2003) 28-35
23. Hesselink D., van Gelder T., van Schaik R., et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphism in the MDR-1, CYP3A4 and CYP3A5 genes. Clin Pharmacol Ther 76 (2004) 545-556
24. Yoshida K., Kimura T., Hamada Y., et al. Comparative study of population pharmacokinetics upon switching of cyclosporine formulation from Sandimmune to Neoral in stable renal transplant patients. Transplant Proc 33 (2001) 3146-3147
25. Cremers S., Scholten E., Schoemaker R., et al. A compartmental pharmacokinetic model of cyclosporin and its predictive performance after Bayesian estimation in kidney and simultaneous pancreas-kidney transplant recipients. Nephrol Dial Transplant 18 (2003) 1201-1208
26. Tokui K., Kimata T., Uchida K., et al. Dose adjustment strategy for oral microemulsion formulation of cyclosporine: population pharmacokinetic based analysis in kidney transplant patients. Ther Drug Monit 26 (2004) 287-294
27. Baraldo M., Pea F., Poz D., and Furlanut M. Pharmacokinetics of two oral cyclosporin A formulations in clinically stable heart-transplant patients. Pharmacol Res 43 (2001) 547-551
28. Green B., and Duffull S. What is the best size descriptor to use for pharmacokinetic studies in the obese?. Br J Clin Pharmacol 58 (2004) 119-133
29. Cheymol G. Effects of obesity on pharmacokinetics. Clin Pharmacokin 39 (2000) 215-231
30. Akhlaghi F., Keogh A., McLachlan A., and Kaan A. Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. J Heart Lung Transplant 20 (2001) 1-8
31. Sheiner L., and Beal S. Some suggestions for measuring predictive performance. J Pharmacokin Biopharm 9 (1981) 503-512
32. Ette E., Williams P., Kim Y., Lane J., Liu M.-J., and Capparelli E. Model appropriatness and population pharmacokinetic modeling. J Clin Pharmacol 43 (2003) 610-623
33. Gomez D., Wacher V., Tomlanovich S., Hebert M., and Benet L. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 58 (1995) 15-19
34. Preuner J., Lehle K., Eichinger H., and Rupprecht L. First-pass metabolism of cyclosporine A in human intestine: inhibition by diltiazem. Transplant Proc 30 (1998) 2545-2546
35. Mahalati K., Belitsky P., Sketris I., West K., and Panek R. Neoral monitoring by simplified sparse sampling area under the concentration time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 68 (1999) 55-62
36. Britto Z., David-Neto E., Lemos F., et al. Identifying cyclosporine blood levels associated with the prevention of renal transplant rejection: a single-centre, randomized prospective study. Transplant Proc 36 (2004) 2649-2655
37. Langers P., Cremers S., Den Hartigh J., et al. Switching monitoring of emulsified cyclosporine from trough level to 2-hour level in stable liver transplant patients. Liver Transplant 10 (2004) 183-189
38. Mardigyan V., Giannetti N., Cecere R., Besner J., and Cantarovich M. Best single time points to predict the area under the curve in long term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus. J Heart Lung Transplant 24 (2005) 1614-1618
39. Scholten E., Cremers S., Schoemaker R., et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int 67 (2005) 2440-2447
40. Marquet P. Clinical application of population pharmacokinetic methods developed for immunosuppressive drugs. Ther Drug Monit 27 (2005) 727-732